GHRP-2

Overview

GHRP-2, also known as pralmorelin, is a synthetic hexapeptide belonging to the growth hormone releasing peptide (GHRP) family. It is classed as a growth hormone secretagogue, meaning it prompts the body’s own pituitary gland to release stored growth hormone rather than supplying hormone directly.

Among the classical GHRPs, GHRP-2 is one of the most studied. It is commonly reported to produce a stronger growth hormone response than GHRP-6, while typically causing less of the marked appetite stimulation associated with that earlier peptide — although research shows GHRP-2 can still increase food intake.

GHRP-2 is the only member of this peptide family to have reached any regulatory approval: it is used in Japan as a diagnostic agent for growth hormone deficiency. Outside of that narrow diagnostic use, it remains unapproved and is sold for research purposes only.

How it works

GHRP-2 binds to the growth hormone secretagogue receptor (GHS-R1a), the same receptor targeted by the natural gut hormone ghrelin. Activating this receptor in the pituitary and hypothalamus is thought to stimulate release of growth hormone from somatotroph cells, and it may also blunt somatostatin, the signal that normally suppresses growth hormone output.

Because it works through a different pathway than growth hormone releasing hormone (GHRH), GHRP-2 is often studied alongside GHRH-analog peptides, where the two are reported to have complementary or additive effects on growth hormone release. The receptor GHRP-2 acts on is also involved in appetite signaling, which is why ghrelin-mimicking peptides can influence hunger.

Reported benefits

• Increased pulsatile release of the body’s own growth hormone (studied in humans and animals)
• Studied as a diagnostic tool for assessing growth hormone deficiency
• Reported interest in recovery, body composition, and sleep quality (largely anecdotal in humans)
• Less pronounced hunger effect than GHRP-6 in some reports, though appetite increase is still documented

These are reported and studied effects, not guaranteed outcomes, and much of the human evidence is limited to diagnostic or short-term research settings.

Considerations & side effects

Human data on GHRP-2 comes mostly from diagnostic testing and small research studies rather than long-term therapeutic trials, so its safety profile with sustained use is not well characterized. Commonly discussed effects include increased appetite, transient changes in prolactin and cortisol, water retention, and injection-site irritation. Because it stimulates growth hormone, there are theoretical concerns around insulin sensitivity and blood sugar with ongoing use.

Purity in the research-chemical market varies, and product quality is not guaranteed. GHRP-2 is not a substitute for evaluation and treatment by a qualified clinician.